RxDoctor Payments Data

Allison Brochtrup

Nurse Practitioner · Brookfield, WINPI 1104405992

Payments from drug & device makers

$2,245in general payments, 2019–2025

Across 97 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$260
  • AstraZeneca$249
  • Boston Scientific$242
  • E.r. Squibb & Sons, L.L.C.$240
  • Novo Nordisk$232
  • Novartis$200
  • plus $823 from 13 others

What the payments were for

  • Food & beverage$2,22599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,245 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$28,607
Medicare patients
207
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$72,377
FarxigaDapagliflozin Propanediol41$44,726
JardianceEmpagliflozin34$41,383
EntrestoSacubitril/Valsartan26$39,138
BrilintaTicagrelor22$24,631
Metoprolol Succinate114$1,307
Atorvastatin Calcium117$1,041
ClopidogrelClopidogrel Bisulfate46$595
Bumetanide33$589
Losartan Potassium62$580
Spironolactone93$501
Carvedilol68$484
Amlodipine Besylate75$476
Rosuvastatin Calcium56$468
Ezetimibe37$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$72,37764 claims
AstraZenecaFarxiga, Brilinta$249$69,35863 claims
Boehringer IngelheimJardiance$16$41,38334 claims
NovartisEntresto$200$39,13826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Brookfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →